Rani Therapeutics Holdings, Inc. Stock Price, News & Analysis

Rani Therapeutics (Nasdaq: RANI) announced the initiation of a Phase 1 study for RT-102, an oral formulation of the human parathyroid hormone analog PTH(1-34) aimed at treating osteoporosis. This study is critical as it utilizes the RaniPill™ capsule to deliver PTH orally, potentially improving patient adherence compared to daily self-injections. Conducted in Australia, the study will evaluate the pharmacokinetics, safety, and tolerability of RT-102 in healthy adult women. Rani aims to revolutionize the delivery of biologics with this innovative oral treatment.

Rani Therapeutics has announced the development of RaniPill™ HC, a high-capacity oral delivery device capable of delivering over 500% more biologic payload than its existing capsule. This device can potentially deliver up to 20mg of biologics, unlocking over 50 new drug opportunities. In preliminary financial results, the company estimates a net loss of $13-15 million for Q4 2021, up from $5.8 million in Q4 2020, and a full-year loss between $53-55 million, compared to $16.7 million in 2020. Cash reserves are approximately $117.5 million.

Rani Therapeutics has appointed Lisa Rometty to its Board of Directors, enhancing its leadership team. With over 25 years of experience in global commercialization and strategic partnerships within healthcare, Rometty aims to advance the RaniPill technology, which seeks to replace subcutaneous injections with oral biologics. CEO Talat Imran emphasized the significance of her expertise in product commercialization for the company’s future. Rani Therapeutics continues to focus on developing and commercializing its innovative RaniPill™ capsule technology, which has shown promise in preclinical and clinical studies.

Rani Therapeutics (Nasdaq: RANI) reported its Q3 2021 financial results, highlighting a net loss of $28.7 million compared to $2.9 million in Q3 2020. R&D expenses surged to $12.0 million, primarily due to increased headcount and equity-based compensation costs. General and administrative expenses soared to $15.8 million from $0.8 million in the prior year. Despite the losses, Rani possesses $129.7 million in cash, expected to sustain operations through at least the end of 2023. The completion of a GLP study for RT-102 and preparations for a Phase I study in 2022 are notable advancements.

Rani Therapeutics Holdings (Nasdaq: RANI) announced the appointment of Lyn Baranowski to its Board of Directors, effective November 12, 2021. Baranowski brings 18 years of experience in the biotechnology sector, having held key roles at Altavant Sciences, Melinta Therapeutics, and AstraZeneca. CEO Talat Imran emphasized her expertise in strategic partnerships and financial transactions, which will be pivotal as Rani progresses its oral biologics delivery technology, RaniPill. This innovation aims to transform patient care by replacing injections with oral alternatives.

Rani Therapeutics (NASDAQ: RANI) announced that CEO Talat Imran will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on November 17, 2021, at 7:00 a.m. PT / 10:00 a.m. ET. The event will focus on the company’s innovative oral delivery system for biologics, utilizing the proprietary RaniPill™ capsule. Interested parties can access the live audio webcast through the company's website. A replay will be available for 30 days.

Rani Therapeutics (Nasdaq: RANI) announced that CEO Talat Imran will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on September 30, 2021, at 9:00 a.m. PT / 12:00 p.m. ET. Interested parties can access the live audio webcast via the Investor Relations section on the company's website. Rani Therapeutics focuses on the oral delivery of biologics, utilizing its proprietary RaniPill™ capsule technology, aimed at improving patient outcomes by replacing traditional injection methods. A replay of the presentation will be available for 30 days post-event.

Rani Therapeutics (Nasdaq: RANI) completed its IPO in July 2021, raising $84.3 million in gross proceeds from the sale of 7,666,667 shares at $11.00 per share. CEO Talat Imran emphasized the company's commitment to advancing oral biologics. As of June 30, 2021, Rani's cash and equivalents stood at $69.3 million, sufficient to fund operations until end of 2023. R&D expenses reached $3.8 million, while general and administrative expenses rose to $3.5 million. The net loss for the quarter was $5.5 million, up from $2.7 million year-over-year.

Rani Therapeutics (Nasdaq: RANI) announced the appointment of Eric Groen as General Counsel, bringing over 25 years of experience in the biopharmaceutical industry. Prior roles include leadership positions at Amgen, where he oversaw legal matters related to business development, operations, and clinical trials. CEO Talat Imran highlights Groen's expertise as crucial for advancing the RaniPill™ capsule technology and the company's clinical pipeline, aiming to replace injections with oral biologics for chronic disease treatment.